- Home
- RNXT vs BEAT Comparison
RNXT vs BEAT Comparison
Compare RNXT & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- BEAT
- Stock Information
- Founded
- RNXT 2012
- BEAT 2015
- Country
- RNXT United States
- BEAT United States
- Employees
- RNXT N/A
- BEAT N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- RNXT Health Care
- BEAT Technology
- Exchange
- RNXT Nasdaq
- BEAT Nasdaq
- Market Cap
- RNXT 44.6M
- BEAT 37.7M
- IPO Year
- RNXT 2021
- BEAT 2021
- Fundamental
- Price
- RNXT $1.25
- BEAT $1.40
- Analyst Decision
- RNXT Strong Buy
- BEAT Buy
- Analyst Count
- RNXT 2
- BEAT 1
- Target Price
- RNXT $7.50
- BEAT $8.00
- AVG Volume (30 Days)
- RNXT 339.0K
- BEAT 124.2K
- Earning Date
- RNXT 08-14-2025
- BEAT 08-13-2025
- Dividend Yield
- RNXT N/A
- BEAT N/A
- EPS Growth
- RNXT N/A
- BEAT N/A
- EPS
- RNXT N/A
- BEAT N/A
- Revenue
- RNXT $662,000.00
- BEAT N/A
- Revenue This Year
- RNXT $2,988.37
- BEAT N/A
- Revenue Next Year
- RNXT $300.60
- BEAT N/A
- P/E Ratio
- RNXT N/A
- BEAT N/A
- Revenue Growth
- RNXT N/A
- BEAT N/A
- 52 Week Low
- RNXT $0.75
- BEAT $0.91
- 52 Week High
- RNXT $1.69
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- RNXT 62.94
- BEAT 61.88
- Support Level
- RNXT $0.90
- BEAT $1.03
- Resistance Level
- RNXT $0.95
- BEAT $1.54
- Average True Range (ATR)
- RNXT 0.08
- BEAT 0.12
- MACD
- RNXT 0.03
- BEAT 0.05
- Stochastic Oscillator
- RNXT 86.54
- BEAT 71.98
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.